ATE395087T1 - Hgf zur gentherapie der karidomyopathie - Google Patents

Hgf zur gentherapie der karidomyopathie

Info

Publication number
ATE395087T1
ATE395087T1 AT00964686T AT00964686T ATE395087T1 AT E395087 T1 ATE395087 T1 AT E395087T1 AT 00964686 T AT00964686 T AT 00964686T AT 00964686 T AT00964686 T AT 00964686T AT E395087 T1 ATE395087 T1 AT E395087T1
Authority
AT
Austria
Prior art keywords
hgf
caridomyopathy
gene therapy
cardiac muscle
cardiac
Prior art date
Application number
AT00964686T
Other languages
English (en)
Inventor
Ryuichi Morishita
Yoshiaki Taniyama
Toshio Ogihara
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE395087T1 publication Critical patent/ATE395087T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00964686T 1999-10-08 2000-10-05 Hgf zur gentherapie der karidomyopathie ATE395087T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28853299 1999-10-08

Publications (1)

Publication Number Publication Date
ATE395087T1 true ATE395087T1 (de) 2008-05-15

Family

ID=17731468

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964686T ATE395087T1 (de) 1999-10-08 2000-10-05 Hgf zur gentherapie der karidomyopathie

Country Status (10)

Country Link
US (1) US6989374B1 (de)
EP (1) EP1136083B1 (de)
JP (1) JP3865632B2 (de)
KR (1) KR20010093804A (de)
CN (2) CN101085363A (de)
AT (1) ATE395087T1 (de)
AU (1) AU775965B2 (de)
CA (1) CA2354029C (de)
DE (1) DE60038869D1 (de)
WO (1) WO2001026694A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100765687B1 (ko) * 1995-08-29 2007-10-11 안제스에무지 가부시키가이샤 Ｈｇｆ 유전자를 함유하는 약제
ATE409494T1 (de) * 1999-10-29 2008-10-15 Anges Mg Inc Gentherapie für diabetische ischämie
JP2005097118A (ja) * 2000-07-18 2005-04-14 Yoshiki Sawa Ｈｇｆ遺伝子からなる細胞移植定着促進剤
AU2001284695A1 (en) 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7247620B2 (en) * 2001-05-09 2007-07-24 Anges Mg, Inc. Method of treating skin wounds with vectors encoding hepatocyte growth factor
EP1435977A4 (de) 2001-09-19 2005-06-08 Ford Henry Health System Herztransplantation von stammzellen zur behandlung von herzinsuffizienz
US7763591B2 (en) 2001-11-28 2010-07-27 Anges Mg, Inc. Hepatocyte growth factor gene therapy for parkinson's disease
US20080213348A1 (en) * 2002-06-06 2008-09-04 Anges Mg, Inc. Agents for gene therapy of cerebrovascular disorders
EP1547618B1 (de) * 2002-10-02 2010-05-26 AnGes MG, Inc. Arzneimittel gegen hörfunktionsstörungen
US20070010436A1 (en) * 2003-04-01 2007-01-11 Yasuhiko Tabata Remedy for cardiomyopathy
JPWO2006046766A1 (ja) * 2004-10-29 2008-05-22 アンジェスＭｇ株式会社 心不全治療のための遺伝子治療
WO2006077675A1 (ja) * 2005-01-24 2006-07-27 Kringle Pharma Inc. 移植臓器の線維化抑制剤
CN101200721B (zh) * 2006-09-18 2011-06-08 复旦大学附属中山医院 人心肌保护基因及其用途
US8247374B2 (en) 2007-11-09 2012-08-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
CA2743682A1 (en) 2007-11-30 2009-06-11 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
CA2743698A1 (en) 2007-11-30 2009-06-11 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
JP4831551B2 (ja) * 2008-11-06 2011-12-07 国立大学法人名古屋大学 非虚血性心筋障害に対する医薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0452457B1 (de) 1989-11-03 1997-08-20 Vanderbilt University Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
DE69133492T2 (de) 1990-06-11 2006-08-10 Nakamura, Toshikazu Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
JP2777678B2 (ja) 1990-06-11 1998-07-23 敏一 中村 組換ヒト肝実質細胞増殖因子及びその製造方法
US5652225A (en) 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
EP0819014B1 (de) * 1995-03-30 2003-02-05 Heartport, Inc. Endovaskulärerkatheter zum ableiten aus dem herz
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
KR100765687B1 (ko) * 1995-08-29 2007-10-11 안제스에무지 가부시키가이샤 Ｈｇｆ 유전자를 함유하는 약제
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
WO1999036103A1 (en) 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
EP1132098B1 (de) 1999-09-21 2010-05-26 AnGes MG, Inc. Gentherapie für zerebrale gefässerkrankungen
ATE409494T1 (de) 1999-10-29 2008-10-15 Anges Mg Inc Gentherapie für diabetische ischämie
CA2490357A1 (en) 2002-06-06 2003-12-18 Anges Mg, Inc. Gene therapeutic for cerebrovascular disorders

Also Published As

Publication number Publication date
CA2354029A1 (en) 2001-04-19
AU775965B2 (en) 2004-08-19
AU7556900A (en) 2001-04-23
CN101085363A (zh) 2007-12-12
JP3865632B2 (ja) 2007-01-10
KR20010093804A (ko) 2001-10-29
CA2354029C (en) 2012-01-10
CN1293922C (zh) 2007-01-10
US6989374B1 (en) 2006-01-24
EP1136083A4 (de) 2005-11-16
DE60038869D1 (de) 2008-06-26
EP1136083A1 (de) 2001-09-26
WO2001026694A1 (fr) 2001-04-19
CN1337884A (zh) 2002-02-27
EP1136083B1 (de) 2008-05-14

Similar Documents

Publication Publication Date Title
DE60038869D1 (de) Hgf zur gentherapie der karidomyopathie
DE60026996D1 (de) Plasmabehandlungsapparat, dessen elektrodenstruktur und struktur der bühne
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
FI961755A0 (fi) Yhdistelmäadenovirusvektori ja menetelmiä sen käyttämiseksi
PL339735A1 (en) Pappiloma virus capsomer vaccine compositions and methods of applying them
GT199500007A (es) 5 derivados sustituidos de acido micofenolico
ATE407949T1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
EP1202736A4 (de) Verwendung von nikotin in der angiogenese und der vaskulogenese
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
ATE320435T1 (de) Oxazolo-, thiazolo- und selenazolo-(4,5- c)naphthyridin-4-amine und analoge davon
GR3036686T3 (en) Therapeutic uses of bactericidal/permeability increasing protein products
NO20005884L (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
ATE232396T1 (de) Oxydiertes thymosin beta 4
WO2003045332A3 (en) Methods and compositions for treating lesions of the respiratory epithelium
CY1108667T1 (el) Ανασυνδυασμενοι φορεις ιου περιεχοντες το ανθρωπινο γονιδιο του ενεργοποιητη πλασμινογονου ουροκινασης και η χρηση τους στην αγωγη της ινωσεως του ηπατος.
WO2000040273A3 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
WO2003039468A3 (en) Antimnemonic therapy for hypermemory syndromes
ATE296894T1 (de) Genverabreichende vektoren mit gewebetropismus für glatte muskelzellen und/oder endothelzellen
NO20040134L (no) Biologisk aktive peptider
EA200200319A1 (ru) Белок iren, его получение и использование
DE60019104D1 (de) Gentherapy von lungenkrankheiten
AU2001268108A1 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
DE69531678D1 (de) Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties